共 201 条
[21]
Pol J(2015)Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer Clin Cancer Res 13 891-3498
[22]
Levesque S(2013)Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer PLoS ONE 18 299-5991
[23]
Petrazzuolo A(2023)Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors EMBO Mol Med 46 447-undefined
[24]
Pfirschke C(2018)3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer Biochem Biophys Res Commun 12 3293-undefined
[25]
Sehgal K(2017)Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing Oncotarget 12 261-undefined
[26]
Piper-Vallillo AJ(2016)Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs Nat Methods 21 6735665-undefined
[27]
Viray H(2020)A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening Commun Biol. 4 3493-undefined
[28]
Khan AM(2020)Kinetics of nuclear uptake and site-specific DNA cleavage during crispr-directed gene editing in solid tumor cells Mol Cancer Res 112 5983-undefined
[29]
Rangachari D(2023)OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening Cell Oncol 22 undefined-undefined
[30]
Costa DB(2012)ROS1 as a “druggable” receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway Expert Rev Anticancer Ther undefined undefined-undefined